Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Gene dosage of the apolipoprotein E (APOE) epsilon 4 allele is a major risk factor for familial Alzheimer disease (AD) of late onset (after age 60). Here we studied a large series of 115 AD case subjects and 243 controls as well as 150 affected and 197 unaffected members of 66 AD families. Our data demonstrate a protective effect of the epsilon 2 allele, in addition to the dose effect of the epsilon 4 allele in sporadic AD. Although a substantial proportion (65%) of AD is attributable to the presence of epsilon 4 alleles, risk of AD is lowest in subjects with the epsilon 2/epsilon 3 genotype, with an additional 23% of AD attributable to the absence of an epsilon 2 allele. The opposite actions of the epsilon 2 and epsilon 4 alleles further support the direct involvement of APOE in the pathogenesis of AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Common variants of the apolipoprotein E gene (APOE) influence the risk of Alzheimer’s disease: APOE4 is linked to high risk, APOE3 is considered to confer a neutral risk, and APOE2 is associated with relative protection.2–5”
From APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer’s Disease (2024) · cites this paper as [5]
Experimental — accuracy not yet measuredIn the citing paper
“APOE, the major susceptibility gene for late-onset AD, has three common alleles (APOE2, 3, and 4).”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Compared to the most common APOE3/3 genotype, which is considered neutral with regard to AD risk, APOE2 is associated with a lower AD risk and older age at dementia onset, and each additional copy of APOE4 is associated with a higher risk and younger age at onset.10”
From Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report (2019) · cites this paper as [10]
In the citing paper
“Apolipoprotein E (APOE), the major susceptibility gene for late-onset Alzheimer’s disease (AD), has three common alleles (APOE2, 3, and 4), giving rise to six genotypes (APOE2/2, 2/3, 3/3, 2/4, 3/4, and 4/4).”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
In the citing paper
“while the presence of one or two copies of the APOE2 allele is associated with a lower risk of Alzheimer’s dementia and an older mean age at dementia onset1–4.”
From Exceptionally low likelihood of Alzheimer’s dementia in APOE2 homozygotes from a 5,000-person neuropathological study (2020) · cites this paper as [2]
38 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Self-citationGoate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationStrittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Self-citationApolipoprotein E: Cholesterol Transport Protein with Expanding Role in Cell Biology
Mahley, R. W. (1988) · Science · doi:10.1126/science.3283935 · Cited by 4,028
Association of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Self-citationDiagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
Self-citationStrittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Self-citationThe Genetic Defect Causing Familial Alzheimer's Disease Maps on Chromosome 21
St George-Hyslop, P. H., Tanzi, R. E., Polinsky, R. J., Haines, J. L., Nee, L., Watkins, P. C., Myers, R. H., Feldman, R. G., Pollen, D., Drachman, D., et al. (1987) · Science · doi:10.1126/science.2880399 · Cited by 1,163
Self-citation
Research works printed but not linked: 2
- Cornoni-Huntley, J., Blazer, D.G., Service, C. & Farmer, M.E. in Established population for epidemiologic studies of the elderly. Volume II (eds Cornoni-Huntley, J. et al.) 1–7 (NIH publication 90–495, Bethesda, 1990).
- Rothman, K.J. Modern Epidemiology. 38–39, 76 (Little, Brown & Company, Boston, 1986).
Cited by
Items 101–200 of 1,029
Deciphering the astrocyte reaction in Alzheimer's disease
Perez-Nievas, B. G., & Serrano-Pozo, A. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00114 · Cited by 282
“By contrast, the ε2 allele is protective against the development of AD (Corder et al., 1994; Serrano-Pozo et al., 2015).”
BackgroundLipid droplets in the nervous system
Ralhan, I., Chang, C.-L., Lippincott-Schwartz, J., & Ioannou, M. S. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202102136 · Cited by 281
Molecular genetics of Alzheimer’s disease
St George-Hyslop, P. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00301-7 · Cited by 265
Hamilton, L. K., Dufresne, M., Joppé, S. E., Petryszyn, S., Aumont, A., Calon, F., Barnabé-Heider, F., Furtos, A., Parent, M., Chaurand, P., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.08.001 · Cited by 284
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange, J., Prechtl, D., Cheburkin, Y. V., Specht, K., Harbeck, N., Schmitt, M., Knyazeva, T., Müller, S., Gärtner, S., Sures, I., et al. (2002) · PubMed · Cited by 312
Human APOE Isoform-Dependent Effects on Brain β-Amyloid Levels in PDAPP Transgenic Mice
Bales, K. R., Liu, F., Wu, S., Lin, S., Koger, D., DeLong, C., Hansen, J. C., Sullivan, P. M., & Paul, S. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0887-09.2009 · Cited by 274
“Conversely, the less frequent 2 allele appears to delay as well as reduce the relative risk for developing AD (Corder et al., 1994).”
BackgroundExploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
Apolipoprotein E allele ∈4, dementia, and cognitive decline in a population sample
Henderson, A. S., Jorm, A. F., Korten, A. E., Christensen, H., Jacomb, P. A., Easteal, S., Croft, L., & Mackinnon, A. J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92405-1 · Cited by 272
The biological pathways of Alzheimer disease: a review
Calabrò, M., Department of Biomedical and Dental Sciences and Morphofunctional Imaging, U. O. M., Rinaldi, C., Santoro, G., & Crisafulli, C. (2021) · AIMS Neuroscience · doi:10.3934/neuroscience.2021005 · Cited by 265
Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review
Minati, L., Edginton, T., Grazia Bruzzone, M., & Giaccone, G. (2009) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317508328602 · Cited by 268
“Conversely, the e2 allele may confer a relative protection.(12) There is also some evidence indicating that variants of the gene encoding for the insulindegrading enzyme (IDE), which is active in the degradation of amyloid-b (Abeta), may predispose individuals to the disease.”
BackgroundBetter Memory and Neural Efficiency in Young Apolipoprotein E 4 Carriers
Mondadori, C. R. A., de Quervain, D. J. F., Buchmann, A., Mustovic, H., Wollmer, M. A., Schmidt, C. F., Boesiger, P., Hock, C., Nitsch, R. M., Papassotiropoulos, A., et al. (2007) · Cerebral Cortex · doi:10.1093/cercor/bhl103 · Cited by 267
Oxidative DNA damage in peripheral leukocytes of mild cognitive impairment and AD patients
Migliore, L., Fontana, I., Trippi, F., Colognato, R., Coppedè, F., Tognoni, G., Nucciarone, B., & Siciliano, G. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.07.016 · Cited by 263
High Density Lipoprotein Structure–Function and Role in Reverse Cholesterol Transport
Lund-Katz, S., & Phillips, M. C. (2010) · Subcellular Biochemistry · doi:10.1007/978-90-481-8622-8_7 · Cited by 262
“The apoE2 allele may be even more protective than apoE3 against the development of Alzheimer’s disease (Corder et al., 1994).”
BackgroundNeuropsychological Measures in Normal Individuals That Predict Subsequent Cognitive Decline
Blacker, D., Lee, H., Muzikansky, A., Martin, E. C., Tanzi, R., McArdle, J. J., Moss, M., & Albert, M. (2007) · Archives of Neurology · doi:10.1001/archneur.64.6.862 · Cited by 261
“Subjects were considered censored at the time that they died, were lost to followup , or developed a dementia other than AD.”
MethodInfluentialGreenberg, S. M., Briggs, M. E., Hyman, B. T., Kokoris, G. J., Takis, C., Kanter, D. S., Kase, C. S., & Pessin, M. S. (1996) · Stroke · doi:10.1161/01.str.27.8.1333 · Cited by 259
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease
Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255
Modulation of Secreted β-Amyloid Precursor Protein and Amyloid β-Peptide in Brain by Cholesterol
Howland, D. S., Trusko, S. P., Savage, M. J., Reaume, A. G., Lang, D. M., Hirsch, J. D., Maeda, N., Siman, R., Greenberg, B. D., Scott, R. W., et al. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.26.16576 · Cited by 255
The cause of neuronal degeneration in Alzheimer’s disease
Vickers, J. (2000) · Progress in Neurobiology · doi:10.1016/s0301-0082(99)00023-4 · Cited by 254
Saunders, A., Hulette, C., Welsh-Bohmer, K., Schmechel, D., Crain, B., Burke, Jr., Alberts, M., Strittmatter, W., Breitner, J., Rosenberg, C., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01251-2 · Cited by 253
Self-citationApolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's disease
Roses, A. D. (1995) · Annals of Neurology · doi:10.1002/ana.410380105 · Cited by 252
Self-citationYoung, J., Modat, M., Cardoso, M. J., Mendelson, A., Cash, D., & Ourselin, S. (2013) · NeuroImage Clinical · doi:10.1016/j.nicl.2013.05.004 · Cited by 249
“The most common allele is APOE ε 3, but carriers of the APOE ε 4 variant are at heightened risk of AD, whereas the APOE ε 2 variant confers some protection on carriers (Corder et al., 1993, 1994).”
BackgroundMethodNagy, Z. S., Esiri, M. M., Jobst, K. A., Johnston, C., Litchfield, S., Sim, E., & Smith, A. D. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00331-c · Cited by 250
Ungar, L., Altmann, A., & Greicius, M. D. (2014) · Brain Imaging and Behavior · doi:10.1007/s11682-013-9272-x · Cited by 246
“It has also been shown that the less common ε2 allele (APOE2) is protective against AD (Corder et al. 1994; Talbot et al. 1994).”
Statement on Use of Apolipoprotein E Testing for Alzheimer Disease
Farrer, L. A. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530200063039 · Cited by 244
Apolipoprotein E and alzheimer's disease: Ethnic variation in genotypic risks
Maestre, G., Ottman, R., Stern, Y., Gurland, B., Chun, M., Tang, M., Shelanski, M., Tycko, B., & Mayeux, R. (1995) · Annals of Neurology · doi:10.1002/ana.410370217 · Cited by 243
Novel allele-dependent role for APOE in controlling the rate of synapse pruning by astrocytes
Chung, W.-S., Verghese, P. B., Chakraborty, C., Joung, J., Hyman, B. T., Ulrich, J. D., Holtzman, D. M., & Barres, B. A. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609896113 · Cited by 242
“The APOE4 allele is significantly overrepresented in lateonset AD patients and has a dosage effect on the risk and age of onset of AD (5), whereas APOE2 is protective against AD (6).”
BackgroundWragg, M., Talbot, C., Hutton, M., & Goate, A. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91140-x · Cited by 242
Apolipoprotein E genotyping in Alzheimer's disease
National Institute on Aging/Alzheimer's Association Working Group, & Relkin, N. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90284-6 · Cited by 241
Sporadic cerebral amyloid angiopathy: pathology, clinical implications, and possible pathomechanisms
Attems, J. (2005) · Acta Neuropathologica · doi:10.1007/s00401-005-1074-9 · Cited by 242
“APOE- 2 decreases the risk of AD [18] but increases the risk of early onset CAA [40, 88] and of hemorrhages in CAA, as APOE- 2 promotes the rupture of Ab-laden”
BackgroundEvidence for impaired amyloid β clearance in Alzheimer's disease
Wildsmith, K. R., Holley, M., Savage, J. C., Skerrett, R., & Landreth, G. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt187 · Cited by 236
Assessment of the genetic variance of late-onset Alzheimer's disease
Ridge, P. G., Hoyt, K. B., Boehme, K., Mukherjee, S., Crane, P. K., Haines, J. L., Mayeux, R., Farrer, L. A., Pericak-Vance, M. A., Schellenberg, G. D., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.02.024 · Cited by 236
Self-citationBondi, M. W., Salmon, D. P., Galasko, D., Thomas, R. G., & Thal, L. J. (1999) · Psychology and Aging · doi:10.1037//0882-7974.14.2.295 · Cited by 235
Hirsch-Reinshagen, V., Maia, L. F., Burgess, B. L., Blain, J.-F., Naus, K. E., McIsaac, S. A., Parkinson, P. F., Chan, J. Y., Tansley, G. H., Hayden, M. R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m508781200 · Cited by 233
Rebeck, G. W., Harr, S. D., Hyman, B. T., & Strickland, D. K. (1995) · Annals of Neurology · doi:10.1002/ana.410370212 · Cited by 232
Childhood-onset schizophrenia: rare but worth studying
Nicolson, R., & Rapoport, J. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00231-0 · Cited by 225
Cholesterol and Alzheimer’s Disease; From Risk Genes to Pathological Effects
Feringa, F. M., & van der Kant, R. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.690372 · Cited by 226
Impact of APOE genotype on neuropathologic and neurochemical markers of Alzheimer disease
Tiraboschi, P., Hansen, L. A., Masliah, E., Alford, M., Thal, L. J., & Corey-Bloom, J. (2004) · Neurology · doi:10.1212/01.wnl.0000128091.92139.0f · Cited by 226
Laws, S. M., Hone, E., Gandy, S., & Martins, R. N. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01615.x · Cited by 223
“It has been shown that APOE e2 alleles are associated with a delayed age of onset of AD (Chartier-Harlin et al. 1994; Corder et al. 1994; Talbot et al. 1994; West et al. 1994; Roses 1995) even in carriers of APP mutations (St George-Hyslop et al. 1994; Sorbi et al. 1995a; 1996).”
BackgroundThe Aging Eye: Common Degenerative Mechanisms Between the Alzheimer's Brain and Retinal Disease
Sivak, J. M. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.12-10827 · Cited by 220
Lee, S. H., Harold, D., Nyholt, D. R., ANZGene Consortium, International Endogene Consortium, the Genetic and Environmental Risk for Alzheimer's disease (GERAD1) Consortium, Goddard, M. E., Zondervan, K. T., Williams, J., Montgomery, G. W., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds491 · Cited by 217
“We also used the weighted probit model (19) fitting the five SNPs in the APOE region, and obtained 4% of the total variance explained by the SNPs.”
BackgroundInfluentialSiemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J., Farlow, M., Ness, D., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 216
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Wijsman, E. M., Pankratz, N. D., Choi, Y., Rothstein, J. H., Faber, K. M., Cheng, R., Lee, J. H., Bird, T. D., Bennett, D. A., Diaz-Arrastia, R., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1001308 · Cited by 214
“The e3/e2 and e2/e2 genotypes were combined because they are each relatively infrequent low-risk genotypes for AD [17].”
BackgroundResultUddin, M. S., Kabir, M. T., Al Mamun, A., Abdel-Daim, M. M., Barreto, G. E., & Ashraf, G. M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-018-1237-z · Cited by 212
“In contrast, there is also evidence that supports the protective roles of APOE2 in patients with AD [29].”
ResultTransgenic models of Alzheimer’s disease: Learning from animals
Spires, T. L., & Hyman, B. T. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.423 · Cited by 212
“allele appears protective.(57) ApoE can bind A 58 and localizes to senile plaques,(59) raising the possibility that this protein plays a role in A clearance.”
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
“The ́2 allele decreases the risk of developing AD; however, this protective effect is not as strong as the risk conferred to carriers of the ́4 allele (17).”
BackgroundHuynh, T.-P. V., Davis, A. A., Ulrich, J. D., & Holtzman, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075481 · Cited by 210
Molecular biology and genetics of Alzheimer's disease
St George-Hyslop, P. H., & Petit, A. (2005) · Comptes Rendus. Biologies · doi:10.1016/j.crvi.2004.10.013 · Cited by 210
Genetics of Alzheimer’s Disease
Chouraki, V., & Seshadri, S. (2014) · Advances in Genetics · doi:10.1016/b978-0-12-800149-3.00005-6 · Cited by 209
Molecular genetics of Alzheimer's disease: An update
Brouwers, N., Sleegers, K., & Van Broeckhoven, C. (2008) · Annals of Medicine · doi:10.1080/07853890802186905 · Cited by 208
“The o2 isoform, on the other hand, was shown to have a protective effect; however, this could not be consistently replicated (213).”
BackgroundDodart, J.-C., Marr, R. A., Koistinaho, M., Gregersen, B. M., Malkani, S., Verma, I. M., & Paul, S. M. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409072102 · Cited by 207
Cognitive reserve and long-term change in cognition in aging and preclinical Alzheimer's disease
Soldan, A., Pettigrew, C., Cai, Q., Wang, J., Wang, M.-C., Moghekar, A., Miller, M. I., & Albert, M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.09.002 · Cited by 205
“Eight individuals with one APOE ε4 and one APOE ε2 allele were excluded from analyses involving APOE ε4 status, since the APOE ε4 allele increases dementia risk (Corder et al., 1993), whereas the APOE ε2 allele reduces dementia risk (Corder et al., 1994).”
BackgroundAncestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations
Rajabli, F., Feliciano, B. E., Celis, K., Hamilton-Nelson, K. L., Whitehead, P. L., Adams, L. D., Bussies, P. L., Manrique, C. P., Rodriguez, A., Rodriguez, V., et al. (2018) · PLOS Genetics · doi:10.1371/journal.pgen.1007791 · Cited by 206
Self-citationGenetic Association Mapping Based on Discordant Sib Pairs: The Discordant-Alleles Test
Boehnke, M., & Langefeld, C. D. (1998) · The American Journal of Human Genetics · doi:10.1086/301787 · Cited by 206
“For an actual data analysis, as in our Alzheimer disease–ApoE example, we would either compute the exact P value or use many more permutations in an effort to estimate the P value to a desired level of accuracy.”
BackgroundResultInfluentialUpdates in Alzheimer's disease: from basic research to diagnosis and therapies
Liu, E., Zhang, Y., & Wang, J.-Z. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00432-x · Cited by 199
“Although there are conflicting reports [50], APOE ε2 ( APOE2 ) is commonly considered as an AD protective and longevity allele [51].”
BackgroundApolipoprotein E and cognitive change in an elderly population
Hyman, B. T., Gomez‐Isla, T., Briggs, M., Chung, H., Nichols, S., Kohout, F., & Wallace, R. (1996) · Annals of Neurology · doi:10.1002/ana.410400111 · Cited by 205
APOE alleles predict the rate of cognitive decline in Alzheimer disease: A nonlinear model
Martins, C. A. R., Oulhaj, A., de Jager, C. A., & Williams, J. H. (2005) · Neurology · doi:10.1212/01.wnl.0000188871.74093.12 · Cited by 205
Cholesterol involvement in the pathogenesis of neurodegenerative diseases
Liu, J.-P., Tang, Y., Zhou, S., Toh, B. H., McLean, C., & Li, H. (2010) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2009.07.013 · Cited by 203
Cell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
“For late-onset AD, which accounts for the vast majority of AD cases, researchers so far have identified only genetic loci that can alter disease risk, the strongest of which is the apolipoprotein E ( APOE ) locus 9,10 .”
APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.194 · Cited by 199
Kemp, S. B., Carpenter, E. S., Steele, N. G., Donahue, K. L., Nwosu, Z. C., Pacheco, A., Velez-Delgado, A., Menjivar, R. E., Lima, F., The, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3929 · Cited by 197
“In Alzheimer’s disease APOE4 is a risk factor for disease (47), while APOE2 plays a protective role (48).”
BackgroundTransethnic genome‐wide scan identifies novel Alzheimer's disease loci
Jun, G. R., Chung, J., Mez, J., Barber, R., Beecham, G. W., Bennett, D. A., Buxbaum, J. D., Byrd, G. S., Carrasquillo, M. M., Crane, P. K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.12.012 · Cited by 197
“The 32 allele is protective [7] such that carriers of this allele have a”
Self-citationIdentification of Novel Genes in Late-Onset Alzheimer's Disease
Pericak-Vance, M. A., Grubber, J., Bailey, L. R., Hedges, D., West, S., Santoro, L., Kemmerer, B., Hall, J. L., Saunders, A. M., Roses, A. D., et al. (2000) · Experimental Gerontology · doi:10.1016/s0531-5565(00)00196-0 · Cited by 197
Self-citationMild Cognitive Impairment: Diagnosis, Longitudinal Course, and Emerging Treatments
Vega, J. N., & Newhouse, P. A. (2014) · Current Psychiatry Reports · doi:10.1007/s11920-014-0490-8 · Cited by 195
Cholesterol Metabolism in Neurodegenerative Diseases: Molecular Mechanisms and Therapeutic Targets
Dai, L., Zou, L., Meng, L., Qiang, G., Yan, M., & Zhang, Z. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02232-6 · Cited by 194
Weeks, D. E., Conley, Y. P., Tsai, H.-J., Mah, T. S., Schmidt, S., Postel, E. A., Agarwal, A., Haines, J. L., Pericak-Vance, M. A., Rosenfeld, P. J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/422476 · Cited by 195
“Apolipoprotein E (APOE [MIM 107741]) alleles have been shown to contribute significantly to the risk of several medical conditions, including Alzheimer disease (AD2 [MIM 104310]) (Corder et al. 1994; Breitner et al. 1998; Meyer et al. 1998).”
BackgroundSelf-citationEmrani, S., Arain, H. A., DeMarshall, C., & Nuriel, T. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00712-4 · Cited by 194
“more, while possession of the APOE2 allele is protective against AD [2, 10, 11], with Caucasian individuals who”
BackgroundRelation between smoking and risk of dementia and Alzheimer disease: The Rotterdam Study
Reitz, C., den Heijer, T., van Duijn, C., Hofman, A., & Breteler, M. M. B. (2007) · Neurology · doi:10.1212/01.wnl.0000271395.29695.9a · Cited by 195
Cholesterol as a causative factor in Alzheimer's disease: a debatable hypothesis
Wood, W. G., Li, L., Müller, W. E., & Eckert, G. P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12637 · Cited by 194
“While the APOE-e2 allele confers some protection against AD (Corder et al. 1994), the APOE-e4 allele is associated with an increased risk of AD (Corder et al. 1993; Poirier et al. 1993).”
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
“Before the seminal genetic studies identifying APOE ε4 as a risk factor for AD 5 and APOE ε2 as protective 7 , APOE was found to co-deposit with both cerebral and systemic amyloid deposits.”
Linkage disequilibrium in European elite maize germplasm investigated with SSRs
Stich, B., Melchinger, A. E., Frisch, M., Maurer, H. P., Heckenberger, M., & Reif, J. C. (2005) · Theoretical and Applied Genetics · doi:10.1007/s00122-005-2057-x · Cited by 193
“An alternative, promising approach is association mapping, which has been successfully applied in human genetics to detect QTL coding for simple as well as complex diseases (Corder et al. 1994; Kerem et al. 1989).”
BackgroundGralle, M., & Ferreira, S. T. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.02.001 · Cited by 191
Animal models of Alzheimer's disease and evaluation of anti-dementia drugs
Yamada, K., & Nabeshima, T. (2000) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(00)00081-4 · Cited by 190
Association of Single-Nucleotide Polymorphisms of the Tau Gene With Late-Onset Parkinson Disease
Martin, E. R. (2001) · JAMA · doi:10.1001/jama.286.18.2245 · Cited by 191
“This may be similar to APOE, for which the APOE- 4 allele is a risk allele for developing Alzheimer disease, whereas the APOE- 2 allele provides a protective effect.(29) However, the third haplotype in our study is fairly uncommon, and thus this undertransmission of the 11121 haplotype may reflect only the expectation…”
MethodTherapeutic strategies for Alzheimer's disease
Wolfe, M. S. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd938 · Cited by 190
“Individuals who have one or two copies of APOE4 are at higher risk for AD, whereas carriers of the APOE2 allele have a lower risk compared with the general populatio”
BackgroundThe neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease
Beffert, U. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00008-3 · Cited by 189
Genetic and host factors for dementia in Down's syndrome
Schupf, N. (2002) · British Journal of Psychiatry · doi:10.1192/bjp.180.5.405 · Cited by 188
Understanding the Amyloid Hypothesis in Alzheimer’s Disease
Paroni, G., Bisceglia, P., & Seripa, D. (2019) · Journal of Alzheimer's Disease · doi:10.3233/jad-180802 · Cited by 187
“2 were discovered to be the main genetic factor increasing [21–25] or decreasing [21, 26–28] the incidence of NIAD.”
Jack, C. R., Petersen, R. C., Xu, Y. C., O'Brien, P. C., Waring, S. C., Tangalos, E. G., Smith, G. E., Ivnik, R. J., Thibodeau, S. N., & Kokmen, E. (1998) · Annals of Neurology · doi:10.1002/ana.410430307 · Cited by 187
Lee, C. Y. D., Tse, W., Smith, J. D., & Landreth, G. E. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.295451 · Cited by 178
“Possession ofAPOE4 alleles confers increased AD risk and an earlier age of onset in a gene dose-dependent manner, whereas inheriting the apoE2 allele is protective (1, 4).”
BackgroundTang, M. X., Maestre, G. E., Tsai, W., Liu, X., Feng, L., Chung, W.-Y., Chun, M. R., Schofield, P. R., Stern, Y., Tycko, B., et al. (1996) · PubMed · doi:10.7916/d80v9r96 · Cited by 185
APOE ε2 is associated with intact cognition but increased Alzheimer pathology in the oldest old
Berlau, D. J., Corrada, M. M., Head, E., & Kawas, C. H. (2009) · Neurology · doi:10.1212/01.wnl.0000343853.00346.a4 · Cited by 185
APOE ε2 is associated with milder clinical and pathological Alzheimer disease
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176
Dementia in Africa: current evidence, knowledge gaps, and future directions
Akinyemi, R. O., Yaria, J., Ojagbemi, A., Guerchet, M., Okubadejo, N., Njamnshi, A. K., Sarfo, F. S., Akpalu, A., Ogbole, G., Ayantayo, T., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12432 · Cited by 184
Self-citationEvidence for defective retinoid transport and function in late onset Alzheimer's disease
Goodman, A. B., & Pardee, A. B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437937100 · Cited by 184
Suri, S., Heise, V., Trachtenberg, A. J., & Mackay, C. E. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.10.010 · Cited by 183
“The !2 allele is associated with a lower risk of AD-related neurodegeneration (Corder et al., 1994), and with increased longevity in general (Drenos and Kirkwood, 2010).”
BackgroundHultman, K., Strickland, S., & Norris, E. H. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.76 · Cited by 183
HDL and cognition in neurodegenerative disorders
Hottman, D. A., Chernick, D., Cheng, S., Wang, Z., & Li, L. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.07.015 · Cited by 182
The Genetics of Alzheimer Disease: Current Status and Future Prospects
Blacker, D., & Tanzi, R. E. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.294 · Cited by 182
Whalley, L. J., Deary, I. J., Starr, J. M., Wahle, K. W., Rance, K. A., Bourne, V. J., & Fox, H. C. (2008) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/87.2.449 · Cited by 180
Genomic variants, genes, and pathways of Alzheimer's disease: An overview
Naj, A. C., Schellenberg, G. D., & for the Alzheimer's Disease Genetics Consortium (ADGC) (2017) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32499 · Cited by 179
“The e4 allele also has a dose-dependent relationship with LOAD susceptibility [Corder et al., 1994; Frisoni et al., 1995] with the relative risks of LOAD for e4 homozygotes and for e3/e4 heterozygotes are approximately 15 and 3, respectively, compared to e3 homozygotes [Farrer et al., 1997].”
ResultFormation and function of apolipoprotein E-containing lipoproteins in the nervous system
Vance, J. E., & Hayashi, H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2010.02.007 · Cited by 155
Noble, E. P. (1998) · Alcohol · doi:10.1016/s0741-8329(97)00175-4 · Cited by 179
Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation
Liao, F., Li, A., Xiong, M., Bien-Ly, N., Jiang, H., Zhang, Y., Finn, M. B., Hoyle, R., Keyser, J., Lefton, K. B., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96429 · Cited by 178
“7-fold for one E4 allele and ~12-fold for 2 E4 alleles relative to the E3/ E3 genotype); in contrast, apoE2 (Cys112, Cys158) is protective for AD (5, 6).”
BackgroundA genome-wide association study implicates the APOE locus in nonpathological cognitive ageing
Davies, G., Harris, S. E., Reynolds, C. A., Payton, A., Knight, H. M., Liewald, D. C., Lopez, L. M., Luciano, M., Gow, A. J., Corley, J., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2012.159 · Cited by 176
Self-citationZhang, X., Mormino, E. C., Sun, N., Sperling, R. A., Sabuncu, M. R., Yeo, B. T. T., Initiative, T. A. D. N., Weiner, M. W., Aisen, P., Weiner, M., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1611073113 · Cited by 178
“The protective effects of the e2 allele (35) might potentially contribute to the observation that the subcortical factor was associated with the mildest decline in both memory and executive function across all stages (Fig.”
BackgroundTansley, S., Uttam, S., Ureña Guzmán, A., Yaqubi, M., Pacis, A., Parisien, M., Deamond, H., Wong, C., Rabau, O., Brown, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28473-8 · Cited by 177
Specific Regional Transcription of Apolipoprotein E in Human Brain Neurons
Xu, P.-T., Gilbert, J. R., Qiu, H.-L., Ervin, J., Rothrock-Christian, T. R., Hulette, C., & Schmechel, D. E. (1999) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65305-9 · Cited by 176
Self-citationGenetic dissection of Alzheimer disease, a heterogeneous disorder.
Schellenberg, G. D. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8552 · Cited by 177
PET amyloid-beta imaging in preclinical Alzheimer's disease
Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 174
Metadata
- Authors
- Corder, E. H., Saunders, A. M., Risch, N. J., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Rimmler, J. B., Locke, P. A., Conneally, P. M., Schmader, K. E., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A.
- Affiliations
- Duke University (US)
- Yale University (US)
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of California, Los Angeles (US)
- Venue
- Nature Genetics
- Published
- 1994-06
- Volume
- 7
- Issue
- 2
- Pages
- 180-184
- ISSN
- 1061-4036 (ISSN-L)
- 1546-1718
- OpenAlex
- W2090271811
- Cited by
- 1,920
- References
- 41
- Citations by year
- 2026: 45 · 2025: 77 · 2024: 78 · 2023: 59 · 2022: 66 · 2021: 76 · 2020: 76 · 2019: 58 · 2018: 62 · 2017: 58 · 2016: 75 · 2015: 55 · 2014: 63 · 2013: 68 · 2012: 66
- FWCI
- 54.52
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Genetics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (NIA AG05128, U24AG021886)
- National Institute of Neurological Disorders and Stroke (P01NS026630, NINDS NS26630, NINDS NS531153)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- apolipoprotein E, APOE ε4, late-onset Alzheimer's disease, familial Alzheimer's disease, gene dosage, protective effect, sporadic Alzheimer's disease, genetic risk factors, APOE genotype
- MeSH terms
- Aged, Alleles, Alzheimer Disease, Apolipoproteins E, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Risk Factors, Odds Ratio, Age of Onset
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.